07 September, 2017
According to the analysts, Dynavax Technologies (NASDAQ:DVAX) is expected to announce $-0.47/share EPS for the current quarter. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company.
Merrimack Pharmaceuticals, Inc. (MACK) has a market capitalization of 165.99 Million which suggests the company is a huge company further suggesting that the shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:ARLZ), its shares were trading at $1.19 a retreat of $0, on the trading floor. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company's stock worth $1,053,000 after acquiring an additional 6,623 shares during the last quarter.
Now the shares of Merrimack Pharmaceuticals, Inc. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company's stock valued at $267,000 after buying an additional 5,618 shares during the last quarter. If you are accessing this news story on another website, it was stolen and reposted in violation of US & global trademark and copyright legislation.
News articles about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive this week, according to Accern Sentiment Analysis.
Latest evolution in the price of Dynavax Technologies Corporation (NASDAQ:DVAX) stock has been one of the most talked about matter among the interested investors. The company has market cap of $174.94 million. Recently, the commodity stands 133.74% away from the 52-week high and -2.81% from the 52-week low.
The stock is now moving with a Positive distance from 200-Day Simple Moving Average of about 161.55% and has a pretty decent Year to Date (YTD) Performance of 382.28% which means the stock is constantly adding to its value from previous fiscal year end price.
Dynavax Technologies Corporation (DVAX) surprised the stock market in its last reported earnings when it earned -$0.41 a piece versus the consensus-estimated -$0.44. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million.
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. Pulmatrix, Inc. (NASDAQ:PULM) earnings have declined with a quarterly rate of 0% over the last 5 years. Analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.
P/E of the company is not reported. William Blair reiterated an "outperform" rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Dynavax Technologies Corporation from a "sell" rating to a "hold" rating in a research note on Friday, August 4th. Royal Bank Of Canada reaffirmed a "buy" rating and set a $26.00 price objective on shares of Dynavax Technologies Corporation in a report on Friday, September 1st. BidaskClub downgraded Dynavax Technologies Corporation from a "buy" rating to a "hold" rating in a report on Monday, July 31st.
Dynavax Technologies Corporation (DVAX) stock price moved 9.22% away from 20-Days Simple Moving Average, 39.40% from 50-Days Simple Moving Average and separated 155.72% from 200 Days Simple Moving Average. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.80, which implies that analysts are generally bullish in their outlook for DVAX over the next year. The company now has an average rating of "Hold" and a consensus price target of $24.80.
Dynavax Technologies has $48 highest and $700 lowest target. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation.
